19 February 2024 - Velsipity is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU.

Pfizer announced today that the European Commission has granted marketing authorisation for Velsipity (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Read Pfizer press release